anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Genetic mutations in critical nodes of pulmonary epithelial function are linked to the pathogenesis of pulmonary fibrosis (PF) and other interstitial lung diseases. The slow progression of these pathologies is often intermitted and accelerated by acute exacerbations, complex non-resolving cycles of inflammation and parenchymal damage, resulting in lung function decline and death. Excess monocyte mobilization during the initial phase of an acute exacerbation, and their long-term persistence in the lung, is linked to poor disease outcome.
METHODS: The present work leverages a clinical idiopathic PF dataset and a murine model of acute inflammatory exacerbations triggered by mutation in the alveolar type-2 cell-restricted Surfactant Protein-C [SP-C] gene to spatially and phenotypically define monocyte/macrophage changes in the fibrosing lung.
RESULTS: SP-C mutation triggered heterogeneous CD68+ macrophage activation, with highly active peri-injured cells relative to those sampled from fully remodeled and healthy regions. Ingenuity pathway analysis of sorted CD11b-SigF+CD11c+ alveolar macrophages defined asynchronous activation of extracellular matrix re-organization, cellular mobilization, and Apolipoprotein E (Apoe) signaling in the fibrosing lung. Cell-cell communication analysis of single cell sequencing datasets predicted pro-fibrogenic signaling (fibronectin/Fn1, osteopontin/Spp1, and Tgfb1) emanating from Trem2/TREM2 + interstitial macrophages. These cells also produced a distinct lipid signature from alveolar macrophages and monocytes, characterized by Apoe expression. Mono- and di-allelic genetic deletion of ApoE in SP-C mutant mice had limited impact on inflammation and mortality up to 42 day after injury.
DISCUSSION: Together, these results provide a detailed spatio-temporal picture of resident, interstitial, and monocyte-derived macrophages during SP-C induced inflammatory exacerbations and end-stage clinical PF, and propose ApoE as a biomarker to identify activated macrophages involved in tissue remodeling.
Administration of NitroMist is contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). PDE5 inhibitors such as sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates. Do not use NitroMist in patients who are taking the soluble guanylate cyclase (sGC) stimulator riociguat. Concomitant use may result in severe hypotension, syncope, or myocardial ischemia.

The time course and dose dependence of this interaction have not been studied, and use within a few days of one another cannot be recommended. Appropriate supportive care for the severe hypotension has not been studied, but it seems reasonable to treat this as a nitrate overdose, with elevation of the extremities and with central volume expansion. The use of any form of nitroglycerin during the early days of acute myocardial infarction requires particular attention to hemodynamic monitoring and clinical status.
PURPOSE: Obesity is a worldwide and growing issue affecting women in childbearing age, complicating surgical procedures as well as pregnancy. Through a reduction of not necessarily required cesarean deliveries-for instance in pregnancies with breech presentation-obesity mediated and surgery-associated morbidity might be contained. Date on the impact of maternal BMI in vaginally attempted breech delivery is not existing. To give insight into whether an elevated BMI leads to an increased perinatal morbidity in vaginally intended deliveries out of breech presentation, we analyzed delivery outcome of laboring women with a singleton baby in breech presentation with overweight and obesity (BMI ≥ 25 kg/m2) in comparison to women with a BMI of below 25 kg/m2.
METHODS: Based on data from January 2004 to December 2020, a cohort study was performed on 1641 women presenting with breech presentation at term (> 37 weeks). The influence of maternal BMI on perinatal outcome was analyzed with Chi2 testing for group differences and logistic regression analysis. Patients with a hyperglycemic metabolism were excluded from the study.
RESULTS: Fetal morbidity was not different when patients with a BMI of ≥ 25 kg/m2 (PREMODA morbidity score 2.16%) were compared to patients with a BMI of below 25 kg/m2 (1.97%, p = 0.821). Cesarean delivery rates were significantly higher in overweight and obese women with 43.9% compared to 29.3% (p < 0.0001). BMI and cesarean delivery were significantly associated in a logistic regression analysis (Chi2 coefficient 18.05, p < 0.0001). In successful vaginal deliveries out of breech presentation, maternal perineal injury rates (vaginal birth in normal-BMI women 48.4%; vaginal birth in overweight and obese women: 44.2%; p = 0.273) and rates of manually assisted delivery (vaginal birth in normal-BMI women: 44.4%; vaginal birth in obese and overweight women: 44.2%; p = 0.958) were not different between BMI groups.
CONCLUSIONS: Obesity and overweight are not associated with peripartum maternal or newborn morbidity in vaginally attempted breech delivery, if the patient cohort is thoroughly selected and vaginal breech delivery is in an upright maternal position. Reduction of cesarean delivery rates, especially in overweight and obese women might, have an important positive impact on maternal and newborn morbidity.
Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1, Day 30 and Day 60 and a single 0.5 mL IM injection of PNEUMOVAX™23 at 12 months after HSCT. Participants will have received HSCT 90 to 180 days prior to Day 1. Those who develop chronic graft-versus-host-disease (GVHD) during the first year after HSCT will receive V114 instead of PNEUMOVAX™23 as their fourth dose.
NEW MATERIAL:A derivative of 4-hyroxytetrahydropyran-2-one expressed by formula I (R1 is H or 2-tetrahydropyranyl; (n) is 1-2; R2 and R3 are H or lower alkyl; R4 is H, lower alkyl, lower alkenyl, aryl, aralkyl, acyl, aroyl or substituted sulfonyl). EXAMPLE:Trans-(+ or -)-6-[5-benzyloxy-2,3-dihydro-6-(2-prophyl)-2,2,4- trimethylbenzo[b]furan-7-yl]ethyl-4-hydroxytetrahydropyran-2-one. USE:A cholesterol lowering agent and lipid lowering agent. The compound expressed by formula I has action capable of inhibiting HMG-CoA reductase. PREPARATION:For example, an aldehyde expressed by formula II is allowed so react with an acetoacetic acid ester to afford a ketoalcohol expressed by formula III. Then the ketoalcohol expressed by formula III is reduced to give a compound expressed by formula IV, which is further hydrolyzed with a base and then subjected to a ring closure by heating to provide the compound expressed by formula I (R1 is H).
PROBLEM TO BE SOLVED: To obtain an antitumor agent highly effective for treating cancer by using dolastatin 10 in combination with other specific compound(s). SOLUTION: This antitumor agent is obtained by using (A) dolastatin 10 or an analog thereof (e.g. a compound of the formula) as an active ingredient in combination with (B) an antitumor agent with, as another kind of active ingredient, at least one compound selected from the group consisting of 5- fluorouracil, doxorubicin, irinotecan, cisplatin, cyclophosphamide, etoposide, and paclitaxel; wherein the ingredient B is pref. 0.1-50 wt.% in content when this antitumor agent is in a solid or semi-solid form, being pref. 0.05-10 wt.% in concentration when the antitumor agent is in a liquid form. The dose of the ingredient A is normally about 0.1 - about 10 mg, pref. about 0.2 - about 5 mg, at one time, while the dose of the ingredient B, depending on the kind, for example, for 5-fluorouracil, is normally about 5 - about 20 mg at one time.
In addition to medication using SSRIs, patients will be also treated with rTMS. The stimulated brain region has decided to be dlpfc. Treatment will last 4 weeks.
Subjects over the age of 18 with both: 1) visually significant cataracts requiring cataract surgery and 2) diabetic macular edema (DME) will be enrolled in the study. Subjects with high risk proliferative diabetic retinopathy and any other retinal vascular disease or retinal pathology that may limit vision will be excluded. Baseline photography will be done to quantify the amount of DME and to exclude the presence of proliferative diabetic retinopathy or other retinal vascular or general retinal pathology. Subjects will be randomized to receive either an intravitreal injection of Ozurdex or Avastin at the time of cataract surgery. Subjects will be monitored the day after surgery, one to two weeks after cataract surgery and again monthly thereafter for a total of six visits from the time of cataract surgery with standardized visual acuity measurement, ophthalmologic examination and retinal photography performed at each visit. For the first two months after cataract surgery, subjects receiving Ozurdex will receive an injection of Avastin if the degree of swelling worsens by more than 10% on photography or the vision decreases. For the first two months after cataract surgery, subjects receiving Avastin will receive repeat injections of Avastin on a monthly basis. For each monthly visit thereafter, both groups will receive an intravitreal injection of Avastin if clinically significant DME is present or if vision declines.
The invention relates to the pharmacy field, in particular to powerful inhalation analgesic which is efficient, safe and convenient. A patient with burns has to suffer from burnt surface background pain, operation pain and breakthrough pain. Analgesic in European countries, America and other developed countries accounts for almost half of burn treatment western medicine expenses. But opiates and morphine analgesia medicines have defects, and accordingly medical staff and patients in a burn department urgently need to seek for the analgesia medicines which are used for acute pain, and are capable of instantly performing analgesia functions, safe, efficient, easy, convenient, and economical. The invention provides the inhalation analgesic which is a mixed gas composed of nitrous oxide (N2O) and oxygen (O2). The concentration ranges from 51% to 80%, and the inhalation analgesic can be placed in a steel cylinder of 2-40 litres for use. The invention further provides application of the inhalation analgesic in preparing early analgesia medicines and quick-acting analgesia medicines for war wounds, burns, pre-hospital care, transportation and hospital admission.
The purpose of the present invention is to achieve excellent operability for endoscopy examinations and make the insertion route to an affected area easier to understand. An image processing unit (11) of a medical video recording and playback system (100) generates video data of a subject on the basis of an image signal from an imaging unit (3). A feature point information generating unit (24) generates feature point information for a frame specified in the video data. A server (4) links the feature point information with the video data and stores the same. A playback control unit (16) controls the playback of past video on the basis of one or more pieces of video data read from the server (4). A compositing unit (12) generates composite image data by combining live video data from the image processing unit (11) and past video data from the playback control unit (16) so that the live video and the past video are displayed at the same time and then outputs the same. A monitor (2) displays a composite image based on the composite image data. The playback control unit (16) performs control so that playback pauses on a frame in the past video data to which feature point information is linked.
This is an experiment measuring EEG to healthy adult probands during mirror therapy and VR mirroring therapy in the upper limb. The experiment will be supplemented by haptic contact and stimulation of the upper limb with a foam roller. According to the instructions, the participants will perform a predetermined movement with one upper limb - clenching the fist. In one part with the mirror, in the other part the sensor for sensing the movement of the hand detects the movement, the software creates the illusion that the patient performs the same movement with the dominant and non-dominant upper limb. The patient sees on the screen the illusion of movement of both of his upper limbs. During therapy, the other upper limb will be tactively stimulated haptically and with a foam roller. Data collection will take place by measuring the electrical activity of the brain using an EEG device. The obtained data will then be processed and evaluated with the help of the sLORETA program. The aim of this work is to compare the brain activity from the above therapies with the resting state of the proband and to focus on the activity of mirror neurons.
Participants randomized to the LIVESTRONG exercise program will attend a 12-week LIVESTRONG Program at one of the participating YMCA's in the greater Boston area or CT. We will have monthly teleconferences to discuss the study, recruitment, and the exercise program. Lastly, throughout the 12-week program, participants will record their attendance at the LIVESTRONG program as well as any exercise done outside of the program. We will provide them with a Physical Activity Log book to record their exercise.
In the first interview at the beginning of the treatment protocol with assisted reproductive techniques, a personal information questionnaire and beck anxiety scale will be applied to the control group selected by the 1-to-1 randomization method. Afterwards, the Beck anxiety scale will be applied again at the end of the treatment without any intervention.
Participants will perform a 100 fall-bounces (5 sets x 20 reps, with two minutes of rest) from a 50 cm high box as the fatigue protocol. All participants will use a five-minute bicycle ergometer to warm up prior to the. Following the fatigue protocol, sports massage will be applied on the quadriceps femoris muscles for five minutes.
Psittacosis is a rare zoonotic disease caused by a gram-negative obligate intracellular bacterium Chlamydia psittaci, which is transmitted through contact with infected birds. It comprises approximately 1% of all community-acquired pneumonia cases. However, this can be just the tip of the iceberg pertaining to the lack of routine testing and awareness of this disease entity, thereby requiring a high index of suspicion for its diagnosis. We report a case of a 37-year-old male presenting with high-grade fever with chills, acute onset of dyspnea, dry cough, arthralgia, and myalgia which was not responding to broad-spectrum empirical antibiotics and supportive care. We started evaluating the patient as a case of pyrexia of unknown origin (PUO), but the fever workup turned out to be inconclusive. This prompted us to revisit the history. It was found that the patient owned a parrot that was sick for the last 15 days. The temporal correlation of the illness with a history of exposure made us suspect psittacosis, which was confirmed by treatment with doxycycline resulting in a drastic improvement in the patient's condition. By this, we want to highlight that history remains the time-tested guide for diagnosing and treating PUO.
This is an unblinded pilot study of 20 patients randomized to either TH plus standard medical care or to standard medical care alone. All patients will undergo pulmonary artery (PA) catheter placement as part of the standard of care for management of cardiogenic shock. Data from the PA catheter is vital in monitoring real-time hemodynamics, initiating vasopressors/inotropes, assessing the response to the therapies, and possible need for escalation of therapy.

For patients randomized to TH, cooling to 32-34°C will then be initiated and maintained for 24 hours using the FDA-approved Intravascular Temperature Management (IVTM™) System with the 9.3 French Quattro® Catheter. The IVTM™ System along with the Quattro® Catheter are currently FDA-approved for use in cardiac surgery patients to achieve and maintain normothermia during surgery and in recovery and to induce, maintain, and reverse mild hypothermia in neurosurgery patients during surgery and in recovery. The IVTM™ System and Quattro® Catheter are not, however, currently FDA-approved to achieve therapeutic hypothermia in cardiogenic shock patients. TH is achieved by circulating normal saline in a closed system through the catheter. The temperature is measured and adjustments are made by the thermal regulation system to automatically maintain target temperature. The target temperature is achieved within 2-3 hours of initiation of TH. Rewarming is accomplished using the same balloon catheter system and heat exchange occurs without infusion of any saline or fluids.

Standard medical therapy for all patients will be based on the current recommendations for management of cardiogenic shock. This includes inotropic therapy for cardiac support, vasopressor therapy to achieve target blood pressure, diuretics for volume removal, and mechanical circulatory support as clinically indicated. Laboratory, echocardiographic, and hemodynamic parameters will be obtained for patients prior to randomization, after 18-24 hours post-randomization, and after 48-96 hours post-randomization. Core temperature will be measured via either thermal tip at the end of a transurethral urinary catheter or endotracheal temperature probe in intubated patients.
The patients in the active group will be taken to the operating room and standard american society of anesthesiologists monitors will be applied. After induction of general anesthesia, the ultrasonographic anatomy of the umbilical region will be studied in each patient. The probe will be adjusted until optimum view of both rectus abdominis muscles, their sheaths and surrounding structures are identified. Once the umbilical region anatomy has been identified the puncture sites will be determined. The puncture sites will be aseptically prepped, the ultrasound probed will be covered with a sterile tegaderm, and sterile ultrasound gel will be used on the field. A 21-g EchoStim echogenic needle will be used. The needle will be inserted in the long axis parallel to the ultrasound probe. The needle will be advanced carefully until the needle tip is seen between the posterior aspect of the rectus muscle and its sheath. After a confirmed negative aspiration, 15 ml of 0.25% bupivacaine will be inserted in 2 ml increments, aspirating in between.

The placebo group will have the exact same procedure performed except 15 ml of normal saline will be injected in each rectus sheath instead of 0.25% bupivacaine. For all patients, when the block has been completed the surgery team will then prep the patient and proceed with the planned operation. The surgery staff and anesthesia providers taking care of the patient in the operating room will be unaware of the patient's group. At this point, all patients will be treated exactly the same. For intubation purposes, all patients will only receive succinylcholine. After intubation, elimination of the succinylcholine dose will be determined using a twitch monitor on the ulnar nerve. If at any point during the surgery, the surgery team needs more muscle relaxation then the anesthesia staff will give appropriate medications.

The first step will be to administer propofol 50mg IV, if hemodynamics allow, and to verify that the patient has 1.0-1.2 minimum alveolar concentration (MAC) of volatile anesthetic. If the patient is not at 1.0 MAC, then the volatile anesthetic should be increased. If this does not provide sufficient relaxation, then a nondepolarizing muscle relaxant will be given in 10mg increments titrated to a train of four of 2 twitches at the ulnar nerve. All patients will receive ofirmev and fentanyl in the operating room for pain control. Ofirmev 1000mg will be given pre-incision to each patient and 1.5 mcg/kg loading dose of fentanyl will be given to each patient. Fentanyl will be redosed in 50mcg increments for a 20% increase in blood pressure or heart rate above preinduction values that is sustained for 5 minutes despite an adequate depth of anesthesia, defined as 1 MAC or greater.
Prolonged hematotoxicity is the most common long-term adverse event in chimeric antigen receptor T cell therapy (CAR-T). To evaluate the impact on prolonged cytopenia of inflammatory status after CAR T infusion, we performed a single-center retrospective study and analyzed patients with B cell lymphomas after CAR-T. Among 90 patients analyzed at 90 days after infusion, the cumulative incidence was 57.5% for prolonged neutropenia, 36.7% for anemia, and 49.8% for thrombocytopenia. Patients who experienced cytokine release syndrome (CRS) had significantly higher incidence and longer duration of prolonged cytopenia. In addition, we found that among patients with grade 1 CRS, those with a longer duration of CRS-related symptoms (>5 days; grade 1b in modified CRS grading [m-CRS]) had a significantly higher incidence and longer duration of prolonged cytopenia than those whose CRS-related symptoms resolved within 5 days (grade 1a m-CRS). Multivariate analysis revealed that a higher m-CRS grade (grade 1b or 2; hazard ratio [HR], 2.42), higher peak CRP (≥10 mg/dL; HR, 1.66), longer duration of elevated CRP (≥10 days; HR, 1.83), and a decrease in serum inorganic phosphorus concentration (≥30% from baseline; HR, 1.95) were associated with significantly higher cumulative incidence of prolonged neutropenia, as well as anemia and thrombocytopenia. Using these factors, we developed a new predictive scoring model for prolonged hematotoxicity, the KyoTox a-score, which can successfully stratify the incidence and duration of cytopenia independent of the existing model, CAR-HEMATOTOX, which is based on laboratory data at lymphodepletion. Thus, this newly developed post-CAR-T inflammation-dependent score is accurate and useful for predicting prolonged hematotoxicity.
The utility model relates to a prescription and a preparation craft of a health food - lecithin sesame paste with the capacity of improving the memory power and the learning capacity. The lecithin has the effect of improving the neurological impediments and the disorders of the frame, recovering the brain function, reinforcing the memory power, preventing the cardiovascular disorders, being anti-aging and other effect. The lecithin is mostly clinically used for treating the hepatitis, the fatty liver, the atherosclerosis, the infantile eczema, the neurosis, the malnutrition, the anemia, the marasmus and other disorders. The utility model has the advantages of boosting the brain power, promoting the nerve synapses in the brain to develop quickly, thereby accelerating the information transmission speed among the neurons in the brain, improving the memory power and the learning capacity, improving the memory power and the aging brain energy of the old people, especially having better effect for the children who are growing and developing. Studies suggest that eating the lecithin has the advantages of helping the brain tissues and the nervous system become healthy, being propitious to eliminate the tiredness, reinforcing the memory power, improving the attention and the learning capacity, activating the brain cells, and improving the symptoms of the impatience and the testiness caused by the mental stress. The lecithin sesame paste can be used as the health food for the children and the old people for improving the memory power, and also can be used for protecting the liver, preventing the fatty liver and the hepatocirrhosis, decreasing the blood-fat, and preventing the arteriosclerosis.